Market Overview

AcelRx Pharma Announces Exercise of Option to Buy Additional Shares

Related ACRX
UPDATE: AcelRX Pharma Says 'We have successfully transitioned ARX-04 into late-stage development, defined the regulatory pathway for ARX-04 and Zalviso in the U.S.'
Earnings Scheduled For March 7, 2016
AcelRx Pharmaceuticals misses by $0.02, beats on revenue (Seeking Alpha)

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), announced today that the underwriters of its public offering have exercised, in full, their option to purchase an additional 1,875,000 shares of common stock at a public offering price of $3.31 per share.  This option to purchase additional shares was granted to the underwriters in connection with AcelRx's previously announced underwritten public offering of 12,500,000 shares of its common stock, which was closed on December 12, 2012.  The sale of option shares was closed on December 14, 2012. With the exercise of this option, the total gross proceeds of the public offering increased to approximately $47.6 million with estimated net proceeds to AcelRx of $44.2 million after deducting underwriting discounts and estimated expenses.

Posted-In: News Offerings


Related Articles (ACRX)

View Comments and Join the Discussion!